Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in August 2011 on request of the Sponsor.
On 2 August 2007, orphan designation (EU/3/07/464) was granted by the European Commission to Novartis Europharm Limited, UK, for panobinostat lactate for the treatment of cutaneous T cell lymphoma.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Treatment of cutaneous T-cell lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Novartis Europharm Limited
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: